


Significant research efforts have been devoted to the development of mineralocorticoid receptor (MR) antagonists as possible therapeutics. Specifically, they have been studied as treatments for a range of medical indications, including hypertension, chronic kidney disease, and congestive heart failure.

Eli Lilly recently published **EL-1**, an MR antagonist that was evaluated as part of a combination therapy with tadalafil (Cialis®) for resistant hypertension.

For this Team Challenge, you are part of a process chemistry team focused on meeting the multikilogram supply needs for clinical evaluation of **EL-1**. Working with your team, propose an efficient, scalable, and stereoselective route to access **EL-1**. You are not permitted to use a computer for this Team Challenge but may ask Keary regarding commercial availability of starting materials.



Mitchell, D. *et al.*, *Org. Process Res. Dev.* **2017**, *21*, 208–217.